Wilmington Savings Fund Society FSB Grows Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Wilmington Savings Fund Society FSB grew its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 193.4% in the third quarter, Holdings Channel.com reports. The firm owned 1,810 shares of the biopharmaceutical company’s stock after acquiring an additional 1,193 shares during the quarter. Wilmington Savings Fund Society FSB’s holdings in Regeneron Pharmaceuticals were worth $1,903,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in REGN. World Investment Advisors LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the third quarter valued at about $44,221,000. Pine Valley Investments Ltd Liability Co raised its position in shares of Regeneron Pharmaceuticals by 19.0% during the 3rd quarter. Pine Valley Investments Ltd Liability Co now owns 5,303 shares of the biopharmaceutical company’s stock valued at $5,575,000 after buying an additional 848 shares during the period. Sculati Wealth Management LLC lifted its holdings in Regeneron Pharmaceuticals by 1.9% in the third quarter. Sculati Wealth Management LLC now owns 2,047 shares of the biopharmaceutical company’s stock valued at $1,970,000 after acquiring an additional 38 shares during the last quarter. Anchor Investment Management LLC grew its position in Regeneron Pharmaceuticals by 212.0% in the third quarter. Anchor Investment Management LLC now owns 858 shares of the biopharmaceutical company’s stock worth $902,000 after acquiring an additional 583 shares during the period. Finally, Morse Asset Management Inc increased its stake in Regeneron Pharmaceuticals by 0.9% during the third quarter. Morse Asset Management Inc now owns 4,807 shares of the biopharmaceutical company’s stock worth $5,053,000 after acquiring an additional 43 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. Morgan Stanley cut their price objective on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. Citigroup started coverage on shares of Regeneron Pharmaceuticals in a report on Thursday, November 14th. They issued a “neutral” rating and a $895.00 price objective on the stock. Wells Fargo & Company cut their target price on Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating on the stock in a research report on Tuesday, October 22nd. Wolfe Research began coverage on Regeneron Pharmaceuticals in a research report on Friday, November 15th. They set an “outperform” rating and a $1,150.00 price target for the company. Finally, Barclays cut their price objective on Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $1,099.90.

Regeneron Pharmaceuticals Stock Down 1.3 %

Regeneron Pharmaceuticals stock opened at $731.30 on Friday. The stock has a market cap of $80.36 billion, a PE ratio of 18.10, a P/E/G ratio of 2.32 and a beta of 0.08. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. The stock’s fifty day moving average is $849.77 and its two-hundred day moving average is $1,003.80. Regeneron Pharmaceuticals, Inc. has a 1-year low of $728.68 and a 1-year high of $1,211.20.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.